Key result
A review of available evidence suggests that acute oxygen supplementation reduces pulmonary vascular resistance by ~20-30% and mean pulmonary arterial pressure by ~10% in patients with PAH.
Why the study?
Supplemental oxygen is not recommended for most PAH patients lacking severe hypoxaemia, prompting an evaluation of whether this reflects available clinical evidence and current scientific understanding of alveolar oxygen effects.
Does supplemental oxygen therapy improve pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension?
Does supplemental oxygen therapy improve pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension?
Supplemental oxygen is a potent pulmonary vasodilator that may benefit PAH patients even without severe hypoxemia, warranting a reevaluation of current guidelines.
Answers are grounded in this paper and cite their sources.
Opens new treatment axis for PAH with poor prognosis on standard drugs; extends evidence for novel agents in RCTs.
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), resulting in right ventricular failure and death. Primary treatment of PAH (Class 1) is based on the use of four classes of drugs in the form of monotherapy or combination therapy. Despite significant advances in drug-based treatment of PAH and improvements in survival rates, the prognosis for PAH patients remains poor.1 PAH drugs target mechanisms involved in vasodilation of pulmonary arterial vessels (Fig. 1A), but their vascular effects are not limited to the pulmonary circulation, probably contributing to side effects and limiting drug efficacy. Thus, there is a need for additional therapeutic approaches. In contrast to PAH drugs, oxygen is a potent and selective pulmonary vasodilator. Yet, the use of supplemental oxygen (i.e. O2 therapy) to treat PAH is often viewed as being outdated and ineffective. Recent guidelines1 do not recommend O2 therapy for PAH patients, except for the minority of patients who develop severe hypoxaemia (percent arterial O2 saturation <91%). These recommendations are based on a single negative finding2 and linked to the prescription of O2 therapy in chronic obstructive pulmonary disease (COPD) patients who develop severe hypoxaemia. As most PAH (Class 1) patients do not develop severe hypoxaemia, this rules out O2 therapy for most patients. But, does this recommendation accurately reflect the available clinical evidence and is it based on current scientific understanding of effects of alveolar O2 on pulmonary arterial vessels? With respect to clinical evidence of acute effects of O2 on the pulmonary circulation, we reviewed nine studies involving a total of 11 cohorts of PAH patients (paediatric and adult) exposed to 100% O2 for 15–30 min under right heart catheter conditions. All but one study showed that O2 significantly reduced PVR by ~20–30% and mPAP by ~10%, without affecting pulmonary capillary wedge pressure or systemic arterial pressure. Thus, very brief supplementation with O2 induces pulmonary vasodilation in PAH patients. There is considerable variation of this effect between patients. In the one study that examined this variation, the effect of O2 supplementation on PVR was not correlated with baseline levels of arterial partial pressure of oxygen (PO2).3 In this study, as well as others, there was evidence of substantial pulmonary vasodilation in patients who were not hypoxaemic. The understanding of how supplementary O2 causes pulmonary vasodilation in PAH patients is based on the knowledge of hypoxic pulmonary vasoconstriction (HPV) and its underlying mechanisms. We assume that any mechanism which mediates pulmonary vasoconstriction in response to a reduction in alveolar PO2 can also mediate the reverse effect, namely, vasodilation of an existing vasoconstricted pulmonary arterial bed (as in PAH) in response to alveolar hyperoxia. For many years, a prevailing scientific view of HPV has been that vascular smooth muscle cells in pulmonary arterial vessels sense changes in O2 levels in alveoli and blood, and then mediate the ensuing vascular response (Fig. 1A). However, recent evidence shows that the alveolar endothelium plays an important role as an oxygen sensor in the setting of HPV and provides a rapid and direct link between changes in alveolar PO2 and pulmonary arterial tone4, 5 (Fig. 1B). This suggests that pulmonary vascular effects of O2 are mediated by alveolar and arterial (oxyhaemoglobin) mechanisms and raises questions about clinical views that consider only the latter mechanism. We speculate that acute exposure to O2 can cause significant pulmonary vasodilation in normoxaemic PAH patients because the response relies more on an alveolar than blood-borne mechanism. With respect to long-term effects of O2 supplementation (O2 therapy), we found five PAH studies which included two case reports, a non-randomized clinical trial and two randomized clinical trials. Four of these studies showed beneficial effects of O2 therapy, whereas only one study (randomised controlled trial) reported negative findings. Current guidelines about O2 therapy for PAH are based on this latter study and its negative findings.2 Although it was a long, well-controlled and randomized study, it had significant limitations related to the location of the study (~2240 m in Mexico City), severity of patients' PAH and associated comorbidities (Eisenmenger's syndrome and severely polycythaemic) and suboptimal efficacy of the O2 dose provided. In contrast, a more recent randomized and well-controlled trial of just 1 week of O2 therapy revealed significant improvements in 6-min walk distance in adults with PAH that were comparable to effects reported in longer clinical trials of pulmonary vasodilator drugs.6 Other evidence from paediatric studies shows that O2 therapy can rapidly reduce mPAP and PVR and improve other clinical signs, even in patients who were not hypoxaemic.7 In our opinion, the available evidence suggests that oxygen is a potent and selective pulmonary vasodilator in PAH patients, that there is a novel alveolar mechanism underlying this effect and that O2 therapy may be beneficial to patients who are not hypoxaemic. The alveolar endothelium appears to be an important therapeutic target suited to the specific pulmonary vascular effects of O2. However, therapeutic efficacy of O2 might depend on the integrity and total surface area of the alveolar barrier, and might be diminished in patients with diseases which directly impact alveoli (e.g. COPD). If this is the case, then more caution is needed when extrapolating pulmonary vascular effects of O2 from one class of PAH to another. Nevertheless, the available evidence shows that O2 therapy has more promise than generally appreciated and warrants more intense investigation.
No takes yet. Share an insight, caveat, or question.
Green et al. (2020) conducted a review in Pulmonary arterial hypertension. Oxygen therapy was evaluated on Pulmonary vascular resistance and mean pulmonary arterial pressure. A review of available evidence suggests that acute oxygen supplementation reduces pulmonary vascular resistance by ~20-30% and mean pulmonary arterial pressure by ~10% in patients with PAH.
Synapse has enriched 10 related papers. Consider them for comparative context: